Novartis
As of the edition of 20 October 2026, Novartis runs 465 drugs, 187 of them marketed; it is on route A at 63 targets and on route B at 87 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Novartis was renamed in 2009.
The records place 16 company names in this family.
- NOVARTIS PHARMACEUTICALS CORP: renamed in 2009
- Aduro Biotech, Inc.: acquired in 2023; successor NOVARTIS PHARMACEUTICALS CORP
- Chinook Therapeutics, Inc.: acquired in 2023; successor NOVARTIS PHARMACEUTICALS CORP
- Regulus Therapeutics Inc.: acquired in 2025; successor NOVARTIS PHARMACEUTICALS CORP
- Talaris Therapeutics Inc.: acquired in 2025; successor NOVARTIS PHARMACEUTICALS CORP
- Avidity Biosciences, Inc.: acquired in 2026; successor NOVARTIS PHARMACEUTICALS CORP
- Endocyte: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 187 |
| Active | 80 |
| Went quiet | 95 |
| Stopped | 91 |
| Withdrawn from market | 3 |
| Status not established | 9 |
| Total | 465 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Metformin | none listed | 4 |
| Everolimus | none listed | 1 |
| Cyclosporine | none listed | 3 |
| Letrozole | Ends 2031 (patent) | 1 |
| Fentanyl | none listed | 6 |
| Imatinib | none listed | 0 |
| Ibuprofen | none listed | 11 |
| Nicotine | none listed | 1 |
| Oxytocin | none listed | 1 |
| Ruxolitinib | Ends 2029 (exclusivity) | 4 |
| Ranibizumab | Ended 2018 (computed from the first US licence) | 0 |
| Amlodipine | none listed | 16 |
| Rifampin | none listed | 0 |
| Valsartan | none listed | 2 |
| Methylphenidate | none listed | 11 |
| Zoledronic acid anhydrous | none listed | 4 |
| Moxifloxacin | none listed | 0 |
| Trametinib | Ends 2030 (patent) | 2 |
| Lapatinib | Ends 2029 (patent) | 2 |
| Pazopanib | none listed | 5 |
| Hydrochlorothiazide | none listed | 4 |
| Estradiol | Ends 2032 (patent) | 6 |
| Diclofenac | none listed | 7 |
| Formoterol | none listed | 2 |
A route B row is one company at one target. 162 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 63 targets, route B at 87 targets.
All 150 rows on route A or B
In the product150 company-target rows on route A or B; 147 are not shown here, and no score is.
See all 150 targets where Novartis needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 562 trials led
- Immune system: 365 trials led
- Skin and connective tissue: 303 trials led